Replies to post #103815 on Biotech Values

[Shengli]

My guess and its only a guess is that

BMY BMS-650032 BMS-790052 NS5A BID

May turn out to be the creme de la creme .

[Shengli]

B-I BI 201335 BI 207127 non-nuke TID/BID

Is BI 207127

a hybrid NS3B/NS4B ?

Tia

[DewDiligence]

Who’s Who in All-Oral HCV Programs

[Updated status of VRTX entry for discontinuation of low-dose
all-oral arm in phase-2 trial. I’m temporarily leaving the BMY
entry pending information from AASLD and BMY’s 3Q10 CC.]

 
          Protease     Other      Non-PI    Dosing 
 Company  Inhibitor   Compound    Class    Frequency  Link 
 VRTX‡    Telaprevir  VX-222     non-nuke    BID      http://clinicaltrials.gov/ct2/show/NCT01080222 
 Roche    ITMN-191    RG7128       nuke     TID/BID   http://clinicaltrials.gov/ct2/show/NCT00801255 
 BMY      BMS-650032  BMS-790052   NS5A      BID      http://clinicaltrials.gov/ct2/show/NCT01012895 
 B-I      BI 201335   BI 207127  non-nuke   TID/BID   http://clinicaltrials.gov/ct2/show/NCT01132313 
 IDIX†    IDX320      IDX184       nuke       qD      † 
 ACHN     ACH-1625    ACH-2928     NS5A       qD      * 
 VRUS       n/a       PSI-7977   nuke/nuke    qD      * 
                     +PSI-938 

‡Low-dose all-oral arm discontinued (#msg-55917569).
*All-oral trial has not started.
†Program on clinical hold pending FDA review of SAE’s in drug-drug-interaction study.